Next-generation Sequencing (NGS) - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 353839
出版日期 內容資訊 英文 127 Pages
商品交期: 2-3個工作天內
全球次世代定序(次世代定序,NGS)市場:成長,趨勢,及預測(2020年∼2025年) Next-generation Sequencing (NGS) - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 127 Pages




第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 臨床診斷的用途的增加
    • 促進市場成長的速度,成本,準確度
    • 傳統的技術(微陣列)的有效率的替換
    • 在藥物研發用途的次世代定序技術的需求
  • 市場阻礙因素
    • 法律上及道德性的問題
    • 複雜的資料解釋和熟練的專家不足
  • 波特的五力分析

第5章 市場區隔

  • 各定序類型
    • 全基因測序
    • 目標重定序
    • 全EXOME定序
    • RNA定序
    • ChIP定序
    • De Novo定序
    • 甲基化定序
  • 各產品類型
    • 設備
    • 試劑、消耗品
    • 服務
  • 各終端用戶
    • 醫院及醫療機關
    • 學術機構
    • 製藥及生物科技企業
  • 各用途
    • 藥物研發/個人化醫療
    • 遺傳基因篩檢
    • 診斷/感染疾病
    • 農業及動物研究
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Agilent Technologies
    • DNASTAR Inc.
    • F. Hoffmann-La Roche Ltd
    • GATC Biotech AG
    • Illumina Inc.
    • Macrogen Inc.
    • Pacific Biosciences of California Inc.
    • PerkinElmer Inc.
    • Qiagen
    • Thermo Fisher Scientific Inc.

第7章 市場機會及今後趨勢


Product Code: 47604

Market Overview

The major factors, such as increasing applications of NGS, speed, cost, and accuracy, efficient replacement for traditional technologies, and drug discovery applications demanding NGS technology are expected to drive the growth of the overall market.

The rapid speed, cost, and accuracy of the NGS technology help in the growth of the market. This is attained with the help of modern DNA sequencing technology, which has contributed to the sequencing of complete DNA sequences of numerous types and species of life. It is also found that NGS is significantly cheaper, quicker, and needs significantly lesser DNA, which helps in the overall growth of the market.

The NGS has the potential to accelerate the early detection of disorders and the identification of pharmacogenetics markers to customize its treatments.

There are various technological advancements in the field of medicine that are growing at a rapid pace and has led to the development of personalized medicine. There are a huge number of applications of next-generation sequencing in personalized medicine. Thus, the development of personalized medicine has opened many avenues for the application of NGS, which could accelerate the market growth.

The current market is also facing challenges, owing to the difficulty in management of large data and complications, associated with Big Data management. In addition, some of the ethical issues associated with whole-genome sequencing, coupled with the lack of awareness among people, are pulling back the growth of the market.

Scope of the Report

As per the scope of this report, NGS is a technology in which millions of DNA strands can be sequenced through massive parallelization; this technique is also known as high throughput sequencing. The low cost, high accuracy and speed, and precise results even from low sample input are the main advantages NGS offers over Sanger's sequencing method. NGS is, therefore, being used to execute various applications, such as biomarker discovery, oncology studies, personalized medicine, and agricultural and animal research, among others. Thus, the NGS market has transformed the genomics and molecular diagnostics landscape.

Key Market Trends

Genetic Screening is the Segment Under Application that is Expected to Grow Fastest During the Forecast Period

In genetic screening, the NGS is highly useful in identifying monogenic diseases with locus heterogeneity, such as blindness, deafness, movement disorders, mitochondrial disease, hereditary cancers, etc. Therefore, NGS has a large number of varied applications through genetic screening in multiple disorders, but their affordability and availability in high-income and low-income countries may differ a lot. The entire genomes are being mapped at affordable costs. Thus, steady growth is expected in the forecast period.

The NGS is also emerging as a powerful promising pathogen-detection method for infectious-disease diagnostics. It helps in the identification and genomic characterization of bacteria, fungi, parasites, and viruses, without the need for prior knowledge of a specific pathogen, directly from clinical specimens. As the diseases caused by infections are increasing in the less-developed countries, the NGS-powered diagnosis of these infections has become the most promising method to detect these infectious diseases. The NGS also has applications in personalized medicine that has started becoming a reality and has been under application by various biotechnology companies.

Asia-Pacific is the Fastest-growing Market and is Expected to Follow the Same Trend over the Forecast Period

The market studied is expected to grow at the fastest pace in Asia-Pacific. The rising focus of the major market players is on delivering advanced, efficient NGS technology to the developing countries, in order to cater to the need for genomic medicines and whole genome sequencing for personalized medicine. In addition, the increasing adoption of NGS technology by the non-government and government bodies, along with increased investment of the private players, is expected to drive the Asian market.

Competitive Landscape

There are major biotech industries that are making large investments on evolving preventive vaccines and therapeutic vaccines that can stop or cure diseases, varying from viruses to cancers. The biotech industry, thus, uses the NGS to develop advanced diagnostic kits, in order to screen for pathological conditions and infectious diseases.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Application in the Clinical Diagnosis
    • 4.2.2 Speed, Cost, and Accuracy to Spur the Market Growth
    • 4.2.3 Efficient Replacement for Traditional Technologies (Microarrays)
    • 4.2.4 Drug Discovery Applications Demanding NGS Technology
  • 4.3 Market Restraints
    • 4.3.1 Legal and Ethical Issues
    • 4.3.2 Interpretation of Complex Data and Lack of Skilled Professionals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Type of Sequencing
    • 5.1.1 Whole Genome Sequencing
    • 5.1.2 Targeted Resequencing
    • 5.1.3 Whole Exome Sequencing
    • 5.1.4 RNA Sequencing
    • 5.1.5 CHIP Sequencing
    • 5.1.6 De Novo Sequencing
    • 5.1.7 Methyl Sequencing
  • 5.2 By Product Type
    • 5.2.1 Instruments
    • 5.2.2 Reagents and Consumables
    • 5.2.3 Services
  • 5.3 By End User
    • 5.3.1 Hospitals and Healthcare Institutions
    • 5.3.2 Academics
    • 5.3.3 Pharmaceutical and Biotechnology Companies
  • 5.4 By Application
    • 5.4.1 Drug Discovery/Personalized Medicine
    • 5.4.2 Genetic Screening
    • 5.4.3 Diagnostics/Infectious Diseases
    • 5.4.4 Agriculture and Animal Research
    • 5.4.5 Other Applications
  • 5.5 Geography
    • 5.5.1 North America
      • United States
      • Canada
      • Mexico
    • 5.5.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.5.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South korea
      • Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.5.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies
    • 6.1.2 DNASTAR Inc.
    • 6.1.3 F. Hoffmann-La Roche Ltd
    • 6.1.4 GATC Biotech AG
    • 6.1.5 Illumina Inc.
    • 6.1.6 Macrogen Inc.
    • 6.1.7 Pacific Biosciences of California Inc.
    • 6.1.8 PerkinElmer Inc.
    • 6.1.9 Qiagen
    • 6.1.10 Thermo Fisher Scientific Inc.